# Endocannabinoid System Research: GLP-1 and Mental Health Insights > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/glp-1-receptor-agonists-mental-health-impact/ > **Published:** 2026-03-03T21:44:42-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T12:01:10-04:00 > **Clinical Summary:** Explore the impact of GLP-1 receptor agonists mental health effects, including their potential to reduce schizophrenia risk in recent genetic research. --- #### Clinical Takeaway GLP-1 receptor agonists, the drug class that includes medications like semaglutide, were examined using Mendelian randomization to determine whether they causally affect the risk of ten common mental health conditions, including depression, anxiety, PTSD, and substance use disorders. This genetic analysis approach helps reduce confounding that limits traditional observational studies. The findings add to a growing body of evidence evaluating whether these widely prescribed metabolic medications carry meaningful psychiatric risks or benefits beyond their primary indications. ### #27 Impact of Glucagon-like Peptide-1 Receptor Agonists on Mental Illness: Evidence from a Mendelian Randomization Study. **Citation:** Xiang Longgang et al. *Impact of Glucagon-like Peptide-1 Receptor Agonists on Mental Illness: Evidence from a Mendelian Randomization Study.* International journal of molecular sciences. 2025. PMID: 40141382. **Study type:** Journal Article, Meta-Analysis  |  **Topic area:** Autism  |  **CED Score:** 10 Design: 6 Journal: 0 N: 0 Recency: 2 Pop: 3 Human: 1 Risk: -2 Why This Matters This Mendelian randomization study provides genetic evidence for potential causal effects of GLP1R agonists on mental illness risk, which is clinically significant given the widespread prescription of these agents for diabetes and obesity management. If validated, these findings could inform psychiatric risk assessment in patients initiating GLP1RA therapy and identify GLP1R signaling as a mechanistic target for psychiatric intervention. The establishment of causal rather than merely associative relationships strengthens the rationale for prospective [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) examining GLP1RA safety and efficacy in primary psychiatric populations. **Quality Gate Alerts:** - Preclinical only **Abstract:** Emerging evidence suggests that glucagon-like peptide-1 receptor (GLP1R) agonists may have potential benefits for mental illnesses. However, their exact effects remain unclear. This study investigated the causal relationship between glucagon-like peptide-1 receptor agonist (GLP1RA) and the risk of 10 common mental illnesses, including attention deficit and hyperactivity disorder, anorexia nervosa, anxiety disorder, autism spectrum disorder, bipolar disorder, major depressive disorder, post-traumatic stress disorder, schizophrenia, [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/), and alcohol use disorder. We selected GLP1RA as the exposure and conducted a Mendelian randomization (MR) analysis. The cis-eQTLs of the drug target gene GLP1R, provided by eQTLGen, were used to simulate the pharmacological effects of GLP1RA. Type 2 diabetes and BMI were included as positive controls. Using data from both the Psychiatric Genomic Consortium and FinnGen, we conducted separate MR analyses for the same disease across these two independent databases. Meta-analysis was used to pool the results. We found genetic evidence suggesting a causal relationship between GLP1RA and a reduced risk of schizophrenia [OR (95% CI) = 0.84 (0.71-0.98), I2 = 0.0%, common effects model]. Further mediation analysis indicated that this effect might be unrelated to improvements in glycemic control but rather mediated by BMI. However, the findings of this study provide insufficient evidence to support a causal relationship between GLP1RA and other mental illnesses. Sensitivity analyses did not reveal any potential bias due to horizontal pleiotropy or heterogeneity in the above results (p > 0.05). This study suggests that genetically proxied activation of glucagon-like peptide-1 receptor is associated with a lower risk of schizophrenia. GLP1R is implicated in schizophrenia pathogenesis, and its agonists may exert potential benefits through weight management. Our study provides useful information for understanding the neuropsychiat Clinical Perspective This Mendelian randomization study suggesting potential causal links between GLP1R agonists and reduced risk of common mental illnesses is intriguing from a mechanistic standpoint, but several important caveats warrant careful interpretation in clinical practice. The study relies on genetic variants as instrumental variables rather than direct clinical observation, which means the findings represent theoretical associations rather than proven therapeutic effects, and the generalizability to real-world cannabis patients remains entirely unclear. Additionally, many patients using [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) may also have metabolic comorbidities or be considering GLP1R agonists for weight management, creating complex confounding scenarios that this genetic approach cannot fully disentangle. Until prospective [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) directly examine GLP1R agonists as adjunctive or primary treatments for the mental health conditions studied, practitioners should view these results as hypothesis-generating rather than actionable evidence, and continue individualized assessment of cannabis use in the context of each patient’s complete medication regimen and mental health trajectory.  |   |  Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [View on PubMed ↗](https://pubmed.ncbi.nlm.nih.gov/40141382/)[Full Text ↗](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11942543/)[DOI ↗](https://doi.org/10.3390/ijms26062741) Nationwide GLP-1 Care Looking for thoughtful, physician-led GLP-1 guidance? CED Clinic offers GLP-1 and metabolic guidance across the United States, including evaluation, prescribing support, side-effect management, and longer-term follow-up for people seeking careful, personalized care. [Learn More](https://cedclinic.com/metabolic/) [Book Now](https://book.squareup.com/appointments/kn3vehwoiz6to6/location/DPV0VF8Y74WA7/services) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Endocannabinoid System & GLP-1 Receptor Mental Health Research](https://cedclinic.com/glp-1-receptor-agonists-mental-health-research/) Explore detailed research on the interaction between the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) and GLP-1 receptor in mental health contexts. [Read More](https://cedclinic.com/glp-1-receptor-agonists-mental-health-research/) [Endocannabinoid System & GLP-1 Receptor Mental Health Evidence](https://cedclinic.com/glp-1-receptor-agonists-mental-health-impact/) Review clinical evidence linking GLP-1 receptor activity with mental health outcomes and [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) function. [Explore Evidence](https://cedclinic.com/glp-1-receptor-agonists-mental-health-impact/) [Cannabinoid Clinical Trials: GLP-1 Receptors and Mental Health](https://cedclinic.com/glp-1-receptor-agonists-mental-health-study/) Discover ongoing clinical trials investigating GLP-1 receptor agonists and their potential mental health benefits in [cannabinoid therapy](https://cedclinic.com/unknown-cannabinoid-receptor-brain-damage-relief/). [Learn More](https://cedclinic.com/glp-1-receptor-agonists-mental-health-study/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Endocannabinoid%20System%20Research%3A%20GLP-1%20and%20Mental%20Health%20Insights&url=https%3A%2F%2Fcedclinic.com%2Fglp-1-receptor-agonists-mental-health-impact%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fglp-1-receptor-agonists-mental-health-impact%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=Endocannabinoid%20System%20Research%3A%20GLP-1%20and%20Mental%20Health%20Insights%20https%3A%2F%2Fcedclinic.com%2Fglp-1-receptor-agonists-mental-health-impact%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).